CD34+ marrow cells + granulocyte-colony stimulating factor

This is a combination therapy consisting of autologous or allogeneic CD34-positive (CD34+) hematopoietic stem/progenitor cells derived from bone marrow and the administration of granulocyte-colony stimulating factor (G-CSF). The primary purpose of this combination is to mobilize and collect hematopoietic progenitor/stem cells for transplantation or to enhance engraftment following myeloablative therapy. - **Mechanism of Action:** - **CD34+ Marrow Cells:** These are multipotent hematopoietic stem/progenitor cells capable of reconstituting the blood and immune system after transplantation. They are identified by expression of the surface marker CD34. - **Granulocyte-Colony Stimulating Factor (G-CSF):** A glycoprotein cytokine that stimulates proliferation, differentiation, and mobilization of neutrophil precursors in the bone marrow. When administered exogenously (as filgrastim or biosimilars), it increases circulating neutrophils and mobilizes CD34+ progenitor/stem cells into peripheral blood for collection by leukapheresis[1][2][4][5][7]. - **Primary Indications:** Used in autologous or allogeneic stem cell transplantation protocols for patients with malignancies such as lymphoma, leukemia, multiple myeloma, or other conditions requiring hematopoietic reconstitution[3][4][6]. - **Clinical Context:** The combination is not a single pharmaceutical product but rather a therapeutic protocol involving both cellular therapy (stem cell infusion) and biologic drug administration.

Other names

CD34+ hematopoietic stem cells + G-CSFCD34+ bone marrow cells + G-CSFCD34-positive marrow cells + granulocyte colony-stimulating factor